P020: Characterisation of mucus in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Kramer, C.(1)*;Ziegler, J.(1);Alzain, N.(1);Schroeter, S.(1);Almalla, A.(2);Elomaa, L.(2);Addante, A.(3);Kuppe, A.(3);Fentker, K.(4);Nazat Martinez Medina, J.(5);Jarquin-Diaz, V.H.(5);Rulff, H.(6);Gradzielski, M.(6);Forslund, S.(5);Mertins, P.(4);Mall, M.(3);Weinhart, M.(2);Glauben, R.(1);Siegmund, B.(1);
(1)Charité - Universitätsmedizin Berlin, Medical Department of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(2)Freie Universität Berlin, Institute of Chemistry and Biochemistry, Berlin, Germany;(3)Charité - Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine- Immunology and Critical Care Medicine, Berlin, Germany;(4)Max Delbrück Center for Molecular Medicine in the Helmholtz Society and Berlin Institute of Health, Proteomics, Berlin, Germany;(5)Max Delbrück Center for Molecular Medicine and Charité University Hospital, Forslund group, Berlin, Germany;(6)Stranski-Laboratorium für Physikalische und Theoretische Chemie, Institut für Chemie, Berlin, Germany;
P021: Microbial metabolite receptors as mediators of pathogenic processes in Inflammatory Bowel Disease.ECCO’23 CopenhagenYear: 2023
Authors: Spathakis, M.(1,2)*;Dovrolis, N.(1,2);Tarapatzi, G.(1,2);Filidou , E.(1,2);Kandilogiannakis, L.(1,2);Valatas, V.(1,3);Drygiannakis, I.(3);Manolopoulos, V.G.(1,2);Kolios, G.(1,2);Arvanitidis, K.(1,2);Vradelis, S.(4);
(1)Democritus University of Thrace, Laboratory of Pharmacology- Department of Medicine, Alexandroupolis, Greece;(2)Democritus University of Thrace, Individualised Medicine & Pharmacological Research Solutions Center IMPReS, Alexandroupolis, Greece;(3)University of Crete, Gastroenterology and Hepatology Research Laboratory- Department of Medicine, Heraklion, Greece;(4)Democritus University of Thrace, Department of Internal Medicine- Department of Medicine, Alexandroupolis, Greece;
P023: Immune-metabolic profiles of creeping fat in relation to degree of severity in Crohn's disease postsurgical recurrence.ECCO’23 CopenhagenYear: 2023
Authors: Suau, R.(1,2)*;Pardina, E.(3);López-Tejero, M.D.(3);Lorén, V.(1,2);Zabana, Y.(2,4);Llaves, M.(1);Cordobilla, B.(3);Cañete, F.(2,5);Guasch, M.(6);Ricart-Jané, D.(3);Mañosa, M.(2,5);Domènech, E.(2,5);Domingo, J.C.(3);Manyé, J.(1,2);
(1)Institut d'Investigació Germans Trias i Pujol IGTP, IBD Research Group, Badalona, Spain;(2)Centro de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain;(3)Universitat de Barcelona, Biochemistry and Molecular Biology Department, Barcelona, Spain;(4)Hospital Universitari Mútua Terrassa, Gastroenterology Departament- IBD Unit, Terrassa, Spain;(5)Hospital Universitari Germans Trias i Pujol HUGTP, Gastroenterology Department, Badalona, Spain;(6)Hospital Parc Sanitari Sant Joan de Déu, Surgery Department, Sant Boi de Llobregat, Spain;
P024: Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Soleto, I.(1)*;Ramirez, C.(1);Gómez, C.(1);Montse, B.(1);García, S.(1);Orejudo, M.(1);Mecado, J.(1);Chaparro, M.(1);P. Gisbert, J.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd- Madrid. Spain, gastrointestinal unit, Madrid, Spain;
P025: Colonic rather than ileal expression of ITGA4/ITGB7 correlates with local intestinal inflammation in IBDECCO’23 CopenhagenYear: 2023
Authors: Csomor, E.(1)*;Gehrmann, U.(2);Monkley, S.(2);Tian, S.(1);Cairns, J.(2);Angermann, B.(2);Khan, E.(3);Nys, J.(4);Marks, D.(5);
(1)AstraZeneca, Translational Science & Experimental Medicine- Research and Early Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;(2)AstraZeneca, Translational Science & Experimental Medicine- Research and Early Development- Respiratory and Immunology R&I, Gothenburg, Sweden;(3)AstraZeneca, Late Clinical Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;(4)AstraZeneca, Bioscience Asthma- Research and Early Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;(5)AstraZeneca, Early Clinical Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;
P026: Cost per Response/Remission analysis of biologic therapies availables in Argentina for the treatment of Bio-exposed patients with moderate-to-severe active Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Elgart, J.(1);Balderramo, S.(2);Calvi, G.(3);Kanevsky, D.(3);Sánchez Gonzalez, Y.(4)*;
(1)CENEXA. Center of Experimental and Applied Endocrinology, Health Economics, La Plata, Argentina;(2)Hospital Privado Universitario de Cordoba, Gastroenterology Department, Cordoba, Argentina;(3)AbbVie Argentina, Market Access, Buenos Aires, Argentina;(4)AbbVie Inc., HEOR Strategy – Ulcerative Colitis, Chicago, United States;
P027: Anorectal Motility Disorders in Inflammatory Bowel Disease patientsECCO’23 CopenhagenYear: 2023
Authors: Costache, R.(1)*;Dimitriu, A.(1,2);Les, A.(1);Gheorghe, C.(1,2);
(1)Fundeni Clinical Institute, Gastroenterology and Hepatology, Bucharest, Romania;(2)“Carol-Davila” University of Medicine and Pharmacy, Gastroenterology, Bucharest, Romania;
P028: Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?ECCO’23 CopenhagenYear: 2023
Authors: Hilley, P.(1,2)*;Wong, D.(1,3);Ma, R.(4);Peterson, A.(1);De Cruz, P.(1,3);
(1)AUSTIN HEALTH, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Melbourne Academic Centre for Health, Melbourne, Australia;(3)University of Melbourne, Department of Medicine- Austin Academic Centre, Melbourne, Australia;(4)Austin Health, Business Intelligence Unit, Melbourne, Australia;
P029: Histopathological characterization of a chronic DSS-induced mouse model of IBD with intestinal fibrosisECCO’23 CopenhagenYear: 2023
Authors: Nielsen, M.H.(1)*;Zachariassen, L.F.(1);Sárvári, A.K.(2);Marstrand-Jørgensen, A.B.(3);Hansen, H.H.(4);Feigh, M.(4);
(1)Gubra, In vivo pharmacology, Hørsholm, Denmark;(2)Gubra, Tissue research, Hørsholm, Denmark;(3)Gubra, Assay & NGS, Hørsholm, Denmark;(4)Gubra, Sales & Marketing, Hørsholm, Denmark;
P031: CKD-506, a new histone deacetylase 6 inhibitor, suppresses immune cells and restores intestinal epithelial functionECCO’23 CopenhagenYear: 2023
Authors: Lee, J.Y.(1);Ma, H.W.(2);Kim, J.H.(2);Park, I.S.(2);Son, M.(2);Ryu, K.H.(3);Shin, J.(3);Kim, W.H.(4);KimResearch professor, S.W.(2)*;Cheon, J.H.(4);
(1)Yonsei University College of Medicine, Department of Medicine, Seoul, Korea- Republic Of;(2)Yonsei University College of Medicine, Graduate School of Medical Science, Seoul, Korea- Republic Of;(3)CKD Pharmaceutical Co., Non-clinical Study, Yongin, Korea- Republic Of;(4)Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;
P032: Distinct immune cell trigger responses in Ulcerative Colitis – Results from an in vivo human intestinal injury modelECCO’23 CopenhagenYear: 2023
Authors: Bronze, M.(1,2)*;Vilstrup Johansen, J.(3);Attauabi, M.(1);Tveiten Bjerrum, J.(1);Ramírez Galera, M.(2);Woetmann, A.(2);Benedict Seidelin, J.(1);
(1)Herlev and Gentofte Hospital, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)University of Copenhagen, Department of Immunology and Microbiology, Copenhagen, Denmark;(3)University of Copenhagen, BRIC Bioinformatics Core Facility, Copenhagen, Denmark;
P033: The assessment of serum cytokines at baseline could predict mucosal healing in patients with Crohn's disease treated with ustekinumab. A prospective study.ECCO’23 CopenhagenYear: 2023
Authors: BertaniMD, L.(1)*;Antonioli, L.(2);Fornili, M.(2);D'Antongiovanni, V.(2);Coppini, F.(1);Ceccarelli, L.(3);Carmisciano, L.(2);Benvenuti, L.(2);Mumolo, M.G.(3);Bottari, A.(1);Baglietto, L.(2);Bellini, M.(1);Fornai, M.(2);De Bortoli, N.(1);Costa, F.(3);
(1)University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy;(2)University of Pisa, Clinical and Experimental Medicine, Pisa, Italy;(3)Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy;
P034: A common IL2RA polymorphism alters natural killer cell immunophenotype and function in Crohn's disease, with implications for IL-2 based therapyECCO’23 CopenhagenYear: 2023
Authors: Clough, J.(1)*;Roberts, L.(2);Goldberg, R.(2);Lord, G.(3);Irving, P.(1);
(1)Guy's and St Thomas' NHS Trust, Gastroenterology, LONDON, United Kingdom;(2)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;(3)University of Manchester, Department of Medicine and Life Sciences, Manchester, United Kingdom;
P035: Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBDECCO’23 CopenhagenYear: 2023
Authors: Tirosh, O.(1);Meshner, S.(1);Eshar, S.(1);Kruger Ben-Shabat, S.(1);Polonski, O.(1);Haber, E.(1);Liu, B.(2);Herzog, J.(2);Sartor, R.B.(2);Ringel, Y.(3)*;
(1)Biomica Ltd., Biomica Ltd., Rehovot, Israel;(2)University of North Carolina, Division of Gastroenterology and Hepatology- Center for Gastrointestinal Biology and Disease, Chapel Hill- NC, United States;(3)Meir Medical Center- affiliated with Tel Aviv University, Division of Gastroenterology and Hepatology, Kfar Saba, Israel;
P036: Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profilesECCO’23 CopenhagenYear: 2023
Authors: Baldan-Martin, M.(1)*;Lloro, I.(2);Azkargorta, M.(2);Ramírez, C.(1);Soleto Fernández, I.(1);Orejudo, M.(1);García, S.(1);Mercado, J.(1);Gordillo, C.H.(3);Riestra, S.(4);Rivero, M.(5);Gutiérrez, A.(6);Rodríguez-Lago, I.(7);Fernández-Salazar, L.(8);Ceballos, D.(9);Benítez, J.M.(10);Aguas, M.(11);Bastón-Rey, I.(12);Bermejo, F.(13);Casanova, M.J.(1);Lorente, R.(14);Ber, Y.(15);Royo, V.(16);Esteve, M.(17);Elortza, F.(2);Gisbert, J.P.(1);Chaparro, M.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Proteomics Platform- CIC bioGUNE- BRTA Basque Research & Technology Alliance- CIBERehd- ProteoRed-ISCIII, Proteomics Platform, Derio, Spain;(3)Anatomía patológica- Hospital Universitario de La Princesa., Anatomía patológica, Madrid, Spain;(4)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(5)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(6)Hospital General Universitario de Alicante- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(7)Hospital Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(8)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(9)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(10)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(11)Health Research Institute IISLaFe and Hospital Universitari i Politecnic La Fe, Gastroenterology Unit, Valencia, Spain;(12)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(13)Hospital Universitario de Fuenlabrada and IDIPAZ, Gastroenterology Unit, Madrid, Spain;(14)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(15)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(16)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(17)Hospital Universitari Mutua Terrasa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Terrasa, Spain;
P037: Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Moniruzzaman, M.(1,2)*;Rewatkar, P.(1);Begun, J.(2);Popat, A.(1);
(1)The University of Queensland, School of Pharmacy, Brisbane, Australia;(2)The University of Queensland, Mater Research Institute, Brisbane, Australia;
P038: Notch pathway in fibrosis: a new anti-fibrotic therapy in Crohn's disease?ECCO’23 CopenhagenYear: 2023
Authors: Marti-Chafer, S.(1);Jimenez-Mallen, E.(1);Mendoza, T.(1);Macias-Ceja, D.C.(2);Bauset, C.(2)*;Seco-Cervera, M.(3);Calatayud, S.(4);Cosin-Roger, J.(4);Barrachina, M.D.(4);Ortiz-Masiá, D.(5);
(1)Universitat de Valencia, Medicine, Valencia, Spain;(2)Universitat de Valencia, Pharmacology, Valencia, Spain;(3)Universitat de Valencia-FISABIO, Pharmacology, Valencia, Spain;(4)Universitat de Valencia-CIBERehd, Pharmacology, Valencia, Spain;(5)Universitat de Valencia-CIBERehd, Medicine, Valencia, Spain;
P039: The disappearance of cell death brakes in inflammatory bowel disease: a step towards molecular healingECCO’23 CopenhagenYear: 2023
Authors: Al-Ani, A.(1)*;Samson, A.(2);Rickard, J.(3);Christensen, B.(4);Murphy, J.(2);
(1)The Royal Melbourne Hospital Melbourne Health, Gastroenterology, Melbourne, Australia;(2)Walter and Eliza Hall Institute of Medical Research, Inflammation Division, Melbourne, Australia;(3)Royal Melbourne Hospital, Anatomical Pathology, Melbourne, Australia;(4)Royal Melbourne Hospital, Gastroenterology, Melbourne, Australia;
